VR Logo

Centessa Pharmaceuticals plc (CNTA) download report


Healthcare | Biotechnology & Pharma Research

Centessa Pharmaceuticals plc (CNTA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.

IPO Date: 28-May-2021

CEO & Director: Dr. Saurabh Saha M.D., Ph.D.

Chief Financial Officer: Dr. Gregory M. Weinhoff M.B.A., M.D., MBA

Listing: NASDAQ: CNTA

Country: United Kingdom

Headquarters: Altrincham,

Website: https://www.centessa.com

Key Facts

Market cap: $432.59 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-196.88 Mln

Cash: $544.47 Mln

Total Debt: $74.80 Mln

Insider's Holding: 1.38%

Liquidity: Low

52 Week range: $2.89 - 25.98

Shares outstanding: 94,041,000

Stock Performance

Time Period Centessa Pharmaceuticals (CNTA) S&P BSE Sensex S&P Small-Cap 600
YTD-59.15-9.49-17.79
1 month2.45-2.87-2.72
3 months-48.83-8.59-12.17
1 Year-80.660.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years9.1712.0010.33
As on 24-Jun-2022
Year Centessa Pharmaceuticals (CNTA) S&P Small-Cap 600 S&P BSE Sensex
20180.00-9.705.87